To ensure your financial investments are being managed honestly, enroll in Stock Watch, our free investment monitoring service for individual and institutional investors.
Frequency Therapeutics, Inc. (FREQ) Made Misstatements Regarding the Potential of its Hearing Loss Treatment FX-322 According to the complaint, Frequency Therapeutics began its Phase
AcelRx Therapeutics, Inc. (ACRX) Made Misstatements in Advertising for its Lead Drug Candidate DSUVIA During the relevant period, defendants made false and/or misleading statements
Washington Prime Group, Inc. (WPG) Made Misstatements Regarding its Deteriorating Financial Condition WPG failed to disclose material adverse facts about the Company’s business, operations, and
Aterian, Inc. (ATER) Made Misstatements Regarding its Business Prospects On December 1, 2020, the Company announced that it had acquired the assets of “leading
RLX Technology Inc. (RLX) Made Misstatements Regarding Its Business Prospects The Registration Statement contained untrue statements of material fact. Specifically, the Registration Statement omitted RLX’s
ChemoCentryx, Inc. (CCXI) Misled Investors Regarding the Company’s Concerns for User Safety After the market closed on November 25, 2019, ChemoCentryx, Inc. (CCXI) announced “Positive
Athenex, Inc. (ATNX) Misled Investors About the Efficacy of its Lead Drug Candidate and the Likelihood the FDA Would Approve its New Drug Application On
Frequency Therapeutics, Inc. (FREQ) Made Misstatements Regarding the Potential of its Hearing Loss Treatment FX-322 Frequency Therapeutics began its Phase 2a trial for FX-322
Tricida, Inc. (TCDA) Misled Shareholders About the Viability of its Clinical Trial and Efficacy of its Lead Drug Candidate Tricida conducted a single Phase
Attorney Advertising. Past results do not guarantee a similar outcome.
Disclaimer | Site Map | Privacy Policy
© 2021 – Robbins LLP
